Fate Therapeutics Stock News

Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

SAN DIEGO, April 22, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the develo

Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock?

The SPDR S&P Biotech ETF is down close to 25% year-to-date but Michael Yee sees several names in this space that look promising at current valuations. Why did XBI recover in recent weeks?

Within the last quarter, Fate Therapeutics (NASDAQ: FATE ) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 1 1 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 1 1 0 0 In the last 3 months, 4 analysts have offered 12-month price targets for Fate Therapeutics. The company has an average price target of $93.25 with a high of $122.00 and a low of $62.00. Below is a summary of how these 4 analysts rated Fate Therapeutics over … Full story available on Benzinga.com

SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that the Company will present at the following upcoming investor conferences:

SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the develop

Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q4 2021 Results - Earnings Call Transcript

Fate Therapeutics press release (NASDAQ:FATE): Q4 GAAP EPS of -$0.72 misses by $0.04.Revenue of $17.07M (+7.4% Y/Y) beats by $5.52M.

Enrollment Ongoing in Multi-dose, Multi-cycle Escalation Cohort of FT596+R at 900 Million Cells per Dose for R/R BCL; Interim Phase 1 Data of 16 Patients Showed 69% ORR and 56% CR in Single-dose Escalation Cohorts of FT596+R at ≥90 Million Cells

Fate Therapeutics (FATE) delivered earnings and revenue surprises of -5.88% and 30.84%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Fate Therapeutics (NASDAQ:FATE) is scheduled to announce Q4 earnings results on Monday, Feb. 28, after market close.The consensus EPS estimate is -$0.66

SAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the develop